Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice

Journal of Applied Physiology

Volumn 109, Issue 5, 2010, Pages 1492-1499

  Morris, C A ^a   Selsby, J T ^a   Morris, L D ^a   Pendrak, K ^a   Sweeney, H L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Calpain; Duchenne muscular dystrophy; Myostatin; Protease inhibitor; Proteasome; Transforming growth factor 1

Indexed keywords

BOWMAN BIRK INHIBITOR; MSTN PROTEIN, MOUSE; MYOSTATIN; PROTEIN KINASE B; SMAD PROTEIN; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ARTICLE; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; FIBROSIS; MALE; METABOLISM; MOUSE; MUSCLE CONTRACTION; MUSCLE STRENGTH; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOSTATIN; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

EID: 78549294502     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01283.2009     Document Type: Article

References (48)

1. Andreetta F, Bernasconi P, Baggi F, Ferro P, Oliva L, Arnoldi E, Cornelio F, Mantegazza R, Confalonieri P. Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol 175: 77-86, 2006.
2. Arbogast S, Smith J, Matuszczak Y, Hardin BJ, Moylan JS, Smith JD, Ware J, Kennedy AR, Reid MB. Bowman-Birk inhibitor concentrate prevents atrophy, weakness, and oxidative stress in soleus muscle of hindlimb-unloaded mice. J Appl Physiol 102: 956-964, 2007.
3. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 95: 15603-15607, 1998.
4. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, Cornelio F, Morandi L, Mantegazza R. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 96: 1137-1144, 1995.
5. Billings PC, St Clair WH, Maki PA, Kennedy AR. Distribution of the Bowman Birk protease inhibitor in mice following oral administration. Cancer Lett 62: 191-197, 1992.
6. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420: 418-421, 2002.
7. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65: 826-834, 2005.
8. Decary S, Hamida CB, Mouly V, Barbet JP, Hentati F, Butler-Browne GS. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul Disord 10: 113-120, 2000.
9. Engel AG, Ozawa E. Dystrophinopathies. In: Myology, edited by Engel A, Franzini-Armstrong C. New York: McGraw-Hill, 2004, p. 961-1025.
10. Frenkel K, Chrzan K, Ryan CA, Wiesner R, Troll W. Chymotrypsinspecific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes. Carcinogenesis 8: 1207-1212, 1987.
11. Fukushima K, Nakamura A, Ueda H, Yuasa K, Yoshida K, Takeda S, Ikeda S. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet Disord 8: 54, 2007.
12. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37: 1974-1984, 2005.
13. Gorospe JR, Tharp M, Demitsu T, Hoffman EP. Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis. Neuromuscul Disord 4: 325-333, 1994.
14. Gorospe JR, Tharp MD, Hinckley J, Kornegay JN, Hoffman EP. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 122: 44-56, 1994. (Pubitemid 24073749)
15. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 30: 645-653, 2004.
16. Granchelli JA, Avosso DL, Hudecki MS, Pollina C. Cromolyn increases strength in exercised mdx mice. Res Commun Mol Pathol Pharmacol 91: 287-296, 1996.
17. Hnia K, Hugon G, Rivier F, Masmoudi A, Mercier J, Mornet D. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am J Pathol 170: 633-643, 2007.
18. Huet C, Li ZF, Liu HZ, Black RA, Galliano MF, Engvall E. Skeletal muscle cell hypertrophy induced by inhibitors of metalloproteases; myostatin as a potential mediator. Am J Physiol Cell Physiol 281: C1624-C1634, 2001.
19. Kennedy AR, Szuhaj BF, Newberne PM, Billings PC. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 19: 281-302, 1993.
20. Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaia NF. [Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor]. Biokhimiia 58: 1437-1444, 1993.
21. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51, 2004.
22. Lee KY, Ho SC, Lin HC, Lin SM, Liu CY, Huang CD, Wang CH, Chung KF, Kuo HP. Neutrophil-derived elastase induces TGF-beta1 secretion in human airway smooth muscle via NF-kappaB pathway. Am J Respir Cell Mol Biol 35: 407-414, 2006.
23. Lee SJ. Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS One 3: e1628, 2008.
24. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98: 9306-9311, 2001.
25. Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem 283: 19371-19378, 2008.
26. Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR, Ware JH. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci 53: 175-180, 2008.
27. Maffia PC, Zittermann SE, Scimone ML, Tateosian N, Amiano N, Guerrieri D, Lutzky V, Rosso D, Romeo HE, Garcia VE, Issekutz AC, Chuluyan HE. Neutrophil elastase converts human immature dendritic cells into transforming growth factor-beta1-secreting cells and reduces allostimulatory ability. Am J Pathol 171: 928-937, 2007.
28. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev CD003725, 2008.
29. McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 162: 1135-1147, 2003.
30. Morris CA, Morris LD, Kennedy AR, Sweeney HL. Attenuation of skeletal muscle atrophy via protease inhibition. J Appl Physiol 99: 1719-1727, 2005.
31. Oreffo VI, Billings PC, Kennedy AR, Witschi H. Acute effects of the Bowman-Birk protease inhibitor in mice. Toxicology 69: 165-176, 1991.
32. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90: 3710-3714, 1993.
33. Prior TW, Bridgeman SJ. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. J Mol Diagn 7: 317-326, 2005.
34. Reddy PA, Anandavalli TE, Anandaraj MP. Calcium activated neutral proteases (milli- and micro-CANP) and endogenous CANP inhibitor of muscle in Duchenne muscular dystrophy (DMD). Clin Chim Acta 160: 281-288, 1986.
35. Sawada H, Nagahiro K, Kikukawa Y, Ban S, Kakefuda R, Shiomi T, Yokosawa H. Therapeutic effect of camostat mesilate on Duchenne muscular dystrophy in mdx mice. Biol Pharm Bull 26: 1025-1027, 2003.
36. Smith IJ, Dodd SL. Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle. Exp Physiol 92: 561-573, 2007.
37. Spencer MJ, Croall DE, Tidball JG. Calpains are activated in necrotic fibers from mdx dystrophic mice. J Biol Chem 270: 10909-10914, 1995.
38. Spencer MJ, Mellgren RL. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum Mol Genet 11: 2645-2655, 2002.
39. Spencer MJ, Tidball JG. Calpain concentration is elevated although net calcium-dependent proteolysis is suppressed in dystrophin-deficient muscle. Exp Cell Res 203: 107-114, 1992.
40. Stevenson EJ, Giresi PG, Koncarevic A, Kandarian SC. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol 551: 33-48, 2003.
41. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280: 9291-9296, 2005.
42. Thompson VF, Saldana S, Cong J, Goll DE. A BODIPY fluorescent microplate assay for measuring activity of calpains and other proteases. Anal Biochem 279: 170-178, 2000.
43. Vigouroux S, Farout L, Clavel S, Briand Y, Briand M. Increased muscle proteasome activities in rats fed a polyunsaturated fatty acid supplemented diet. Int J Biochem Cell Biol 35: 749-755, 2003.
44. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344: 133-138, 1997.
45. Whitehead NP, Yeung EW, Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 33: 657-662, 2006.
46. Yavelow J, Collins M, Birk Y, Troll W, Kennedy AR. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress xray- induced transformation in vitro. Proc Natl Acad Sci USA 82: 5395-5399, 1985.
47. Zhang Y, Kouzuma Y, Miyaji T, Yonekura M. Purification, characterization, and cDNA cloning of a Bowman-Birk type trypsin inhibitor from Apios americana Medikus tubers. Biosci Biotechnol Biochem 72: 171-178, 2008.
48. Zhao XY, Zhao LY, Zheng QS, Su JL, Guan H, Shang FJ, Niu XL, He YP, Lu XL. Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 310: 159-166, 2008.